Pharma giants battle over COVID-19 patents in London courts
Two key players in the COVID-19 vaccine story – Pfizer/BioNTech and Moderna – have begun the latest chapter of their global legal battle over patents concerning technology for the development of mRNA therapeutics such as the COVID-19 vaccines.
In the most recent phase of their legal battles, pharmaceutical heavyweights Pfizer and Moderna are in the UK courts with competing lawsuits regarding the mRNA technology that formed the basis for each company’s respective COVID-19 vaccine. These lawsuits are only a part of the ongoing global litigations between the two companies. Moderna has claimed that Pfizer/BioNTech copied mRNA technology that the former patented well before the onset of the COVID-19 pandemic. Pfizer/BioNTech have argued that the work Moderna claims to have pioneered are simply improvements on previous work.
Moderna’s Spikevax vaccine and Pfizer/BioNTech’s Comirnaty emerged as the most profitable vaccines to emerge from the pandemic. Spikevax generated US$18.4 billion in 2022 for Moderna. Pfizer earned $US37.8 billion for their vaccine in 2022, splitting the profits with BioNTech, who emerged with US$17 billion. The vaccines were the first of their kind to be approved using mRNA technology, instructing cells to create their own version of the SARS-CoV-2 spike protein and inducing an immune response.
The London lawsuits are set to be held over three separate trials. Issues raised include disputed patents on vaccines for respiratory viruses based on mRNA technology, while others focus on how these technologies are delivered. One lawsuit will take into consideration Moderna’s pledge at the beginning of the pandemic not to enforce patents for vaccines “intended to combat the pandemic”. However, the pledge was amended in March 2022 to seek damages after this period. The argument hinges on when the pandemic was officially declared as ‘ended’. Pfizer/BioNTech are expected to dispute Moderna’s ability to withdraw this pledge given that the WHO did not declare an end to COVID-19 as a ‘global health emergency’ until March 2023.
Litigations in other countries and regulatory regions are holding their own parallel trials, with proceedings occurring in Germany, the Netherlands, Belgium, and the United States. Whatever the verdict, the result is expected to hold significant impact for European courts under the European Patent Convention.
Sources:
1. Pfizer vs Modern battle over COVID vaccine patents begins in UK [Accessed April 23, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-vs-moderna-battle-over-covid-vaccine-patents-begins-uk-2024-04-23/
2. COVID vaccine makers to clash in London over mRNA patent dispute [Accessed April 24, 2024] https://www.ft.com/content/41d9ec34-4bea-445f-98f4-27a20b9f4445
Related News
-
News Women in Pharma: Diversi‘tea’ at CPHI North America
CPHI North America will unite the pharmaceutical supply chain in Philadelphia from May 7–9, 2024 for 3 days of innovation and connections. As part of the content Agenda, our Diversity Track will bring the industry together to discuss the imperati... -
News CPHI Online Webinar Series – Optimising Pharma Manufacturing through Digital Transformations
This month’s CPHI Webinar Series explored achieving manufacturing excellence in pharma through the digitalisation of daily processes. Presented by Joe Doyle, Head of Sales at EviView, and Bikash Chatterjee, President and Chief Scientific Of... -
News Western pharma groups warn of supply disruptions over China anti-spy law
China’s anti-espionage laws have caused concern among western pharmaceutical groups over potential arrests or denial of access for foreign inspectors in China-based facilities and manufacturing partners, posing a risk to the supply of drug produc... -
News More to celebrate at the CPHI Milan Pharma Awards 2024
The CPHI Milan Pharma Awards, which are now open for nominations until 18 May 2024, celebrate the innovators making a difference. This year, two new categories have been added to further honour the contributions of a diverse range of pharma professiona... -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance